US biotechnology company MaxScientific Inc announced on Tuesday that it has signed a strategic licensing agreement with Seragon Biosciences Inc, a research-based biopharmaceutical company.

Under this agreement MaxScientific will license a series of biotech and pharmaceutical technologies from Seragon Biosciences to be integrated into the next generation of Revigorator, MaxScientific's flagship nutraceutical for ageing and longevity optimisation.

Brandon West, MaxScientific senior product manager, said: "By applying Seragon Biosciences' expertise in clinical research and pharmaceutical technologies, we are setting a new standard for interventions targeting critical biological mechanisms implicated in cellular ageing. The next iteration of Revigorator will feature novel, cutting-edge ageing intervention technologies, including those engineered to optimise ingredient delivery, enhance cellular NAD+ (nicotinamide adenine dinucleotide) and activate autophagy."